InflaRx vs Kiora Pharmaceuticals
IFRX and KPRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IFRX and KPRX compare
Kiora Pharmaceuticals scores higher on the StockData Score (6 against 5 for InflaRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IFRX | KPRX |
|---|---|---|
| Size and price | ||
| Market cap | – | $5.4M |
| Share price | $1.17 | $1.23 |
| Change, 1 year | −19.9% | −46.6% |
| Change, 5 years | −75.4% | −99.8% |
| Beta (5Y) | 1.47 | 0.80 |
| Employees | – | 3,500 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 0.4× |
| FCF yield | – | −145% |
| Growth | ||
| Revenue growth (TTM) | −82.3% | – |
| Profitability | ||
| Gross margin | −24678% | – |
| Return on equity | – | −67.7% |
| Return on invested capital | – | −1063% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 4.13 | 7.91 (better) |
| Altman Z-score | – | −10.67 |
| Piotroski F-score | – | 3 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 135% | 25.0% |
| Held by insiders | 6.0% | 3.0% |
Go deeper
- IFRX stock overview
- IFRX income statement
- IFRX valuation and score
- KPRX stock overview
- KPRX income statement
- KPRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.